Travere Therapeutics Quarterly Income Statement
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics revenue and earnings
In the quarter ended Jun 30, 2026, Travere Therapeutics generated $169.6 million in revenue, up 48.2% from the same quarter a year earlier. Travere Therapeutics reported a net loss of $34.8 million, compared with a loss of $12.8 million a year earlier. Gross margin was 98.7% (flat year over year) and operating margin 2.3%.
Diluted earnings per share came in at -$0.37.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169.58M | 127.20M | 129.69M | 164.86M | 114.45M | 81.73M | 74.79M | 62.90M | 54.12M | 41.37M | 45.06M | 37.09M |
| Revenue growth (YoY) | +48.17% | +55.63% | +73.41% | +162.11% | +111.49% | +97.54% | +65.98% | +69.56% | +68.08% | +33.95% | +53.58% | +32.13% |
| Cost of Revenue | 2.17M | 1.95M | 2.55M | 1.58M | 1.52M | 4.68M | 2.55M | 1.63M | 2.06M | 1.50M | 4.56M | 1.29M |
| Gross Profit | 167.41M | 125.25M | 127.14M | 163.27M | 112.93M | 77.05M | 72.23M | 61.27M | 52.05M | 39.87M | 40.49M | 35.81M |
| Operating Expenses | 163.46M | 162.16M | 159.56M | 138.34M | 125.58M | 119.73M | 132.97M | 117.42M | 119.76M | 179.11M | 134.73M | 128.39M |
| Research & Development | 60.28M | 57.09M | 57.87M | 51.89M | 49.36M | 46.89M | 62.07M | 51.68M | 54.33M | 49.42M | 59.75M | 0 |
| Selling, General & Admin | 96.11M | 80.25M | 101.69M | 86.45M | 62.58M | 60.41M | 69.50M | 65.62M | 64.78M | 64.22M | 63.59M | 67.80M |
| Operating Income | 3.95M | -36.91M | -32.43M | 24.93M | -12.65M | -42.67M | -60.74M | -56.15M | -67.70M | -139.24M | -94.23M | -92.58M |
| Interest Expense | 2.13M | 2.30M | 2.30M | 2.75M | 2.85M | 2.86M | 2.82M | 2.78M | 2.79M | 2.80M | 2.80M | 2.80M |
| Other Income (Expense) | -38.95M | 193.00K | 11.36M | 783.00K | -85.00K | 1.49M | 397.00K | 1.31M | -1.86M | 3.47M | 5.71M | 3.36M |
| Pretax Income | -35.00M | -36.72M | -21.07M | 25.71M | -12.73M | -41.19M | -60.34M | -54.84M | -69.57M | -135.77M | -88.53M | -89.23M |
| Income Tax | -204.00K | -120.00K | 921.00K | 8.00K | 20.00K | 39.00K | -72.00K | -84.00K | 85.00K | 191.00K | 68.00K | 12.00K |
| Net Income | -34.80M | -37.10M | 2.73M | 25.71M | -12.76M | -41.23M | -60.26M | -54.81M | -70.41M | -136.06M | -90.17M | 150.74M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -136.36% | — | — | — | — |
| EPS (Basic) | -0.37 | -0.40 | 0.03 | 0.29 | -0.14 | -0.47 | -0.71 | -0.70 | -0.91 | -1.76 | -1.18 | 1.97 |
| EPS (Diluted) | -0.37 | -0.40 | 0.04 | 0.28 | -0.14 | -0.47 | -0.71 | -0.70 | -0.91 | -1.76 | -1.18 | 1.97 |
| Shares Outstanding (Basic) | 93.48M | 91.87M | — | 89.23M | 88.95M | 88.36M | — | 77.78M | 77.50M | 77.14M | — | 76.31M |
| Shares Outstanding (Diluted) | 93.48M | 91.87M | — | 102.62M | 88.95M | 88.36M | — | 77.78M | 77.50M | 77.14M | — | 76.31M |
| EBITDA | 8.19M | -11.70M | -14.29M | 40.72M | 1.37M | -29.87M | -48.65M | -44.91M | -57.36M | -129.36M | -84.75M | -81.11M |
| Gross Margin | 98.72% | 98.47% | 98.03% | 99.04% | 98.67% | 94.28% | 96.59% | 97.41% | 96.19% | 96.36% | 89.87% | 96.53% |
| Operating Margin | 2.33% | -29.02% | -25.00% | 15.12% | -11.05% | -52.21% | -81.21% | -89.27% | -125.11% | -336.53% | -209.13% | -249.59% |
| Net Margin | -20.52% | -29.17% | 2.10% | 15.59% | -11.14% | -50.44% | -80.58% | -87.14% | -130.11% | -328.86% | -200.12% | 406.35% |
This table shows 12 quarterly periods of Travere Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TVTX's reporting calendar. What is a income statement?